Leal Health Leverages Generative AI to Optimize Cancer Treatment Matching for Patients

Leal Health, formerly known as Trialjectory, has unveiled a groundbreaking addition to its patient-centric, AI-powered treatment platform for cancer care. The company announced the integration of generative AI (GenAI) capabilities, a patented technology that aims to bridge the gap between precision medicine and cancer patients seeking effective treatment options.

This innovative leap marks a significant advancement in overcoming the challenges associated with AI, specifically in understanding unique patient journeys, avoiding consistent errors, and mitigating hallucinations.

According to Tzvia Bader, Leal Health’s Co-Founder and CEO, the integration of GenAI with the platform’s existing natural language processing and machine learning models addresses these challenges effectively. The combination of GenAI’s Large Language Model (LLM) with Leal’s technology allows for the accurate analysis and interpretation of complex patient medical conditions and treatment criteria.

Leal Health’s precise medical modeling patented technology empowers patients to upload their medical records directly to the platform, receiving clear, easy-to-understand explanations of their results. This facilitates accurate treatment matches tailored to individual medical data, enabling patients to make informed decisions about their treatment journeys. Moreover, the GenAI integration enhances the platform’s predictive capabilities, foreseeing a patient’s future treatment pathway by comparing their medical state to similar patients’ past and current conditions and future treatment options. This proactive approach enables pharmaceutical companies to identify and educate potential patients in advance.

Bader emphasizes that Leal is leveraging the power of GenAI to revolutionize global access to precise cancer treatment. By optimizing the treatment matching process, Leal ensures that patient preferences are considered, and biases are overcome. The integration also benefits biopharma companies, allowing them to utilize the platform to remove barriers and biases in their treatments, ensuring accessibility to the patients who need them the most.

Leal Health, recognized by TIME as one of “The 100 Best Inventions of 2020,” has been lauded for its patient-first approach. The company collaborates directly with patients, healthcare providers, and pharmaceutical companies to democratize access to advanced cancer treatment. Leal’s platform empowers the pharmaceutical and biotech industry to conduct patient-centric clinical trials and increase access to standard-of-care therapies.

In addition to improving the patient experience, the GenAI integration positions Leal Health as a tool for biopharma companies to navigate obstacles in treatment accessibility and ensure that their innovations reach the cancer patients who can benefit the most.

As a leader in the AI-powered healthcare space, Leal Health continues to demonstrate its commitment to revolutionizing cancer care, earning recognition such as being named an honoree in the AI and data category for Fast Company’s “2021 World-Changing Ideas Awards.” The company’s mission is to drive positive change in the cancer treatment landscape by leveraging cutting-edge technology and patient-focused strategies.

Related posts:

Sumitomo Pharma’s ORGOVYX Receives Health Canada Approval for Advanced Prostate Cancer Treatment Roche Avastin: Investigation Launched As 12 Patients Go Blind After Receiving The Cancer Drug Ipsen and Exelixis Set to Transform Prostate Cancer Treatment with Cabometyx and Tecentriq Combo A unique approach to cancer treatment: Piazza and his pharmacy team bring a new approach to cancer research at Auburn University